MedPath

Biomarkers in the blood and skeletal muscle for the improvement of viral myocarditis diagnostics

Recruiting
Conditions
viral infection of the heart
viral myocarditis
10028593
10047438
Registration Number
NL-OMON47465
Lead Sponsor
Vrije Universiteit Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
200
Inclusion Criteria

In the viral myocarditis group patients will be included when they are mentally competent and when they present with suspected viral myocarditis (show flu-like symptoms combined with acute loss of heart function) and comply to the ESC/ACC position statement for endomyocardial biopsy. In the AMI group (controls) patients will be included when they are mentally competent and present with an acute myocardial infarction. Because viral myocarditis can mimic AMI, we will also include patients who present with infarct-like complaints, but show non-occluded epicardial coronary arteries with coronary angiography. Based on subsequent MRI analyses, these patients will later be subdivided into the AMI group (in case of myocardial infarction with non-occluded coronary arteries (MINOCA)) or the viral myocarditis group.

Exclusion Criteria

In the viral myocarditis group the main exclusion criteria are: acute myocardial infarction, prednisolon use or fear of MRI. In the AMI group the main exclusion criteria are to suffer from a viral infection (including HIV). In both groups prednisolon use and mental incompetence is an exclusion cirteria.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>De primary study parameters are the differences in biomarker profile (in heart,<br /><br>blood and skeletal muscle) between viral myocarditis (and the potential<br /><br>subgroups within this group) and acute myocardial infarction patients, as well<br /><br>as the determination of virus type and titer in relation to the pathophysiology<br /><br>of these (sub)groups.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>N.A.</p><br>
© Copyright 2025. All Rights Reserved by MedPath